Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Ra Medical SystemsDynatronicsLianluo SmartOphectra Real Estate and InvestmentsHancock Jaffe Laboratories
SymbolNYSE:RMEDNASDAQ:DYNTNASDAQ:LLITOTCMKTS:MTTCFNASDAQ:HJLI
Price Information
Current Price$3.71$1.08$8.62$0.83$5.82
52 Week RangeHoldBuyN/AN/ABuy
MarketRank™
Overall Score1.31.30.50.00.5
Analysis Score3.03.50.00.00.0
Community Score2.12.32.70.02.3
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score1.30.60.00.00.0
Analyst Ratings
Consensus RecommendationHoldBuyN/AN/ABuy
Consensus Price Target$28.50$1.65N/AN/AN/A
% Upside from Price Target668.19% upside52.78% upsideN/AN/AN/A
Trade Information
Market Cap$12.09 million$16.17 million$19.06 million$10.27 million$49.49 million
Beta1.62-0.040.16N/A1.58
Average Volume344,8071,769,575975,684117,744582,420
Sales & Book Value
Annual Revenue$7.20 million$53.41 million$380,000.00N/A$30,000.00
Price / Sales1.680.3050.15N/A1,649.78
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$61.81 per share$0.81 per share($0.59) per shareN/A$1.38 per share
Price / Book0.061.33-14.61N/A4.22
Profitability
Net Income$-56,960,000.00$-3,420,000.00$-4,450,000.00N/A$-7,630,000.00
EPS($108.25)($0.42)N/AN/AN/A
Trailing P/E RatioN/AN/A0.000.000.00
Forward P/E RatioN/A108.00N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-772.04%-7.94%N/AN/AN/A
Return on Equity (ROE)-120.68%-35.41%N/AN/A-459.46%
Return on Assets (ROA)-85.93%-9.85%N/AN/A-166.13%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.06%0.52%N/AN/AN/A
Current Ratio4.62%2.00%2.42%N/A3.12%
Quick Ratio4.30%1.22%2.17%N/A3.12%
Ownership Information
Institutional Ownership PercentageN/A7.52%28.75%N/A10.14%
Insider Ownership Percentage2.40%9.50%22.90%N/A4.20%
Miscellaneous
Employees8519028N/A12
Shares Outstanding3.26 million14.98 million2.21 million12.30 million8.50 million
Next Earnings Date5/11/2021 (Confirmed)5/13/2021 (Estimated)6/30/2021 (Estimated)N/A6/14/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) – Analysts’ Revisions Show An Improving SentimentHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) – Analysts’ Revisions Show An Improving Sentiment
stocksregister.com - April 18 at 5:07 AM
Comparing Hancock Jaffe Laboratories (NASDAQ:HJLI) and Avinger (NASDAQ:AVGR)Comparing Hancock Jaffe Laboratories (NASDAQ:HJLI) and Avinger (NASDAQ:AVGR)
americanbankingnews.com - April 14 at 3:22 PM
Hancock Jaffe Laboratories, Inc.: First U.S. Patent Issues on Hancock Jaffe VenoValveHancock Jaffe Laboratories, Inc.: First U.S. Patent Issues on Hancock Jaffe VenoValve
finanznachrichten.de - April 7 at 6:28 PM
First U.S. Patent Issues on Hancock Jaffe VenoValveFirst U.S. Patent Issues on Hancock Jaffe VenoValve
finance.yahoo.com - April 7 at 6:28 PM
Why Hancock Jaffes Stock is Trading Higher TodayWhy Hancock Jaffe's Stock is Trading Higher Today
msn.com - April 5 at 1:15 PM
Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal TrialHancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial
finance.yahoo.com - April 5 at 8:14 AM
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) Sees Large Increase in Short InterestHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) Sees Large Increase in Short Interest
americanbankingnews.com - March 30 at 12:18 PM
Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal TrialHancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial
finance.yahoo.com - March 8 at 9:40 AM
Hancock Jaffe Laboratories, Inc.: First U.S. Patent Allowed on Hancock Jaffe VenoValveHancock Jaffe Laboratories, Inc.: First U.S. Patent Allowed on Hancock Jaffe VenoValve
finanznachrichten.de - February 24 at 3:17 PM
First U.S. Patent Allowed on Hancock Jaffe VenoValveFirst U.S. Patent Allowed on Hancock Jaffe VenoValve
finance.yahoo.com - February 24 at 3:17 PM
Hancock Jaffe completes $41M offeringHancock Jaffe completes $41M offering
massdevice.com - February 12 at 3:10 PM
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) surprises Wall Street with -17.65% stock price lossHancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) surprises Wall Street with -17.65% stock price loss
marketingsentinel.com - February 11 at 11:16 PM
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Completes $41 Million Public OfferingHancock Jaffe Laboratories, Inc.: Hancock Jaffe Completes $41 Million Public Offering
finanznachrichten.de - February 11 at 6:16 PM
Hancock Jaffe Completes $41 Million Public OfferingHancock Jaffe Completes $41 Million Public Offering
finance.yahoo.com - February 11 at 6:16 PM
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Laboratories Announces Pricing of Upsized $36 Million OfferingHancock Jaffe Laboratories, Inc.: Hancock Jaffe Laboratories Announces Pricing of Upsized $36 Million Offering
finanznachrichten.de - February 9 at 1:29 PM
Hancock Jaffe Laboratories Announces Pricing of Upsized $36 Million OfferingHancock Jaffe Laboratories Announces Pricing of Upsized $36 Million Offering
finance.yahoo.com - February 9 at 1:29 PM
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDAHancock Jaffe Laboratories, Inc.: Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA
finanznachrichten.de - January 12 at 11:48 AM
Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDAHancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA
finance.yahoo.com - January 12 at 11:48 AM
Hancock Jaffe Announces Executive PromotionsHancock Jaffe Announces Executive Promotions
finance.yahoo.com - December 30 at 7:30 PM
Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing RequirementsHancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements
finance.yahoo.com - December 21 at 11:50 AM
Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing RequirementsHancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements
finance.yahoo.com - December 21 at 11:50 AM
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day MilestoneHancock Jaffe Laboratories, Inc.: Hancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day Milestone
finanznachrichten.de - December 18 at 12:12 AM
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Announces Significant Improvements in all Study Endpoints For Final VenoValve First-in-Human DataHancock Jaffe Laboratories, Inc.: Hancock Jaffe Announces Significant Improvements in all Study Endpoints For Final VenoValve First-in-Human Data
finanznachrichten.de - December 18 at 12:12 AM
Hancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day MilestoneHancock Jaffe Reports Two CoreoGraft Patients Have Reached 30 Day Milestone
finance.yahoo.com - December 16 at 1:33 PM
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Announces One Year Follow-up Data on Eleventh VenoValve PatientHancock Jaffe Laboratories, Inc.: Hancock Jaffe Announces One Year Follow-up Data on Eleventh VenoValve Patient
finanznachrichten.de - December 16 at 8:33 AM
DateCompanyBrokerageAction
3/23/2021Ra Medical SystemsMaxim GroupReiterated Rating
11/29/2020Ra Medical SystemsPiper SandlerLower Price Target
3/11/2020Ra Medical SystemsCantor FitzgeraldLower Price Target
8/13/2019Ra Medical SystemsPiper Jaffray CompaniesDowngrade
3/26/2019Ra Medical SystemsSunTrust BanksReiterated Rating
2/15/2021DynatronicsAegisReiterated Rating
7/2/2020DynatronicsLADENBURG THALM/SH SHReiterated Rating
2/13/2019DynatronicsRoth CapitalLower Price Target
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.